Evidence map›Paper›PMID 22876963›Full record

ArticleJournal of the American Chemical Society2012

Metavanadate at the active site of the phosphatase VHZ.

Vyacheslav I Kuznetsov, Anastassia N Alexandrova, Alvan C Hengge

Open access · greenAbstract read
In one paragraph

Article in Journal of the American Chemical Society, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Vyacheslav I KuznetsovDepartment of Chemistry and Biochemistry, Utah State University, Logan, Utah 84322-0300, USA.
Anastassia N Alexandrova
Alvan C Hengge
Utah State University · USUniversity of California, Los Angeles · US

Funding

Mechanisms of Phosphoryl TransferR01GM047297 · NIGMS · UTAH STATE UNIVERSITY · PI HENGGE, ALVAN C · 2000 to 2010
$2.4M
MECHANISMS OF ACYL AND PHOSPHORYL TRANSFERR29GM047297 · NIGMS · UTAH STATE UNIVERSITY · PI HENGGE, ALVAN C · 1995 to 2000
$36k
NIGMS NIH HHS GM 47297NIGMS NIH HHS R01 GM047297NIGMS NIH HHS R29 GM047297
6 · The paper itself

Abstract

Vanadate is a potent modulator of a number of biological processes and has been shown by crystal structures and NMR spectroscopy to interact with numerous enzymes. Although these effects often occur under conditions where oligomeric forms dominate, the crystal structures and NMR data suggest that the inhibitory form is usually monomeric orthovanadate, a particularly good inhibitor of phosphatases because of its ability to form stable trigonal-bipyramidal complexes. We performed a computational analysis of a 1.14 Å structure of the phosphatase VHZ in complex with an unusual metavanadate species and compared it with two classical trigonal-bipyramidal vanadate-phosphatase complexes. The results support extensive delocalized bonding to the apical ligands in the classical structures. In contrast, in the VHZ metavanadate complex, the central, planar VO(3)(-) moiety has only one apical ligand, the nucleophilic Cys95, and a gap in electron density between V and S. A computational analysis showed that the V-S interaction is primarily ionic. A mechanism is proposed to explain the formation of metavanadate in the active site from a dimeric vanadate species that previous crystallographic evidence has shown to be able to bind to the active sites of phosphatases related to VHZ. Together, the results show that the interaction of vanadate with biological systems is not solely reliant upon the prior formation of a particular inhibitory form in solution. The catalytic properties of an enzyme may act upon the oligomeric forms primarily present in solution to generate species such as the metavanadate ion observed in the VHZ structure.

Indexed as

Catalytic DomainEnzyme InhibitorsModels, MolecularProtein Tyrosine PhosphatasesQuantum TheoryVanadatesEnzyme InhibitorsProtein Tyrosine PhosphatasesVanadates

Identifiers

PMID22876963
PMCPMC3482157
OpenAlexW1976515091

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.